Patent · US Active

Predictive biomarker for cancer treatment with ADCC-enhanced antibodies

US9360481B2 · kind B2 · utility

1Cited by

0References

7Claims

0Family size

Assignee

Roche Glycart AG · CH

Inventors

Lilla Di Scala · Basel, CH
Stefan Evers · Mettmann, DE
Christian Gerdes · Küsnacht (ZH), CH
Christoph Mancao · Weil am Rhein, DE
Alexandre Passioukov · Brussels, BE
Pablo Umana · Wollerau, CH

Key dates

Filing date	Jan 21, 2014
Grant date	Jun 7, 2016
Priority date	—
Expiry date	Jan 21, 2034

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.